KP Tissue (KPT) AI Stock Analysis

• Market Cap: C$110.15M
• Dividend Yield: 7.04%
• Average Volume (3M): 17.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.40
• Revenue Growth: N/A
• EPS Growth: -39.19%
• Country: CA
• Employees: 2,700
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 0.60
• Shares Outstanding: 10,022,337
• 10 Day Avg. Volume: 14,081
• 30 Day Avg. Volume: 17,752
• PEG Ratio: -0.23
• Price to Book (P/B): 1.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$11.00
• Price Target Upside: 0.92% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): 0.74
• Revenue Forecast (FY): C$2.30B

• Rating: 62 Neutral
• Price Target: C$11.00 ▲(0.92% Upside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is primarily held back by inconsistent profitability and uneven/unclear latest cash flow in the provided statements, despite a strong low-leverage balance sheet. Offsetting this, technicals show a clear uptrend with positive momentum, and the earnings call indicated strong recent operating performance and credible long-term capacity expansion plans. Valuation is mixed, with a high dividend yield but a relatively high P/E.

Positive Factors

Revenue Growth

Achieving record revenue reflects strong market demand and effective sales strategies, indicating a robust growth trajectory for the company.

Strong Balance Sheet

A strong balance sheet with no leverage enhances financial stability and provides flexibility for future investments and growth opportunities.

Market Share Expansion

Increasing market share in the facial tissue category strengthens competitive positioning and supports long-term revenue growth.

Negative Factors

Profitability Challenges

Ongoing profitability challenges can hinder reinvestment in growth initiatives and impact long-term financial health.

Tariff Exposure

Significant tariff exposure poses a risk to cost structures and pricing strategies, potentially affecting margins and profitability.

Decline in Consumer EBITDA Margin

A declining EBITDA margin in the consumer segment suggests pressure on cost management and pricing power, impacting overall profitability.

KP Tissue Business Overview & Revenue Model

Company Description

KP Tissue Inc., through its interest in Kruger Products L.P., produces, distributes, markets, and sells a range of disposable tissue products in Canada and the United States. The company operates through two segments, Consumer and Away-From-Home. It offers bathroom and facial tissues, paper towels, and napkins, as well as manufactures private label tissue products. The company markets its products under the Cashmere, Purex, SpongeTowels, Scotties, White Swan, White Cloud, Chalet, Embassy, White Swan, and Metro brand names. The company sells its products to consumers through traditional retail channels, such as grocery stores, mass merchandisers, club and drug stores, convenience stores, and online retailers; and through distributors to businesses involved in commercial users in the property management, healthcare, food services, manufacturing, lodging industries, and public facilities. KP Tissue Inc. was incorporated in 2012 and is headquartered in Mississauga, Canada.

How the Company Makes Money

KP Tissue makes money through its equity interest in Kruger Products L.P., which generates revenue by manufacturing and distributing tissue products across North America. The company earns money by selling these products to major retailers, wholesalers, and commercial clients. Key revenue streams include sales from branded consumer products and private label offerings. Additionally, Kruger Products L.P. engages in strategic partnerships and has a robust distribution network that enhances its market reach, thereby contributing to its earnings.

KP Tissue Financial Statement Overview

Summary

Financials are mixed. The balance sheet is a strength (no debt reported, stable equity base), but profitability has been inconsistent with losses in multiple years and only modest positive net income in 2024. Cash flow durability is also unclear given uneven history and missing/zero 2024 cash flow detail in the provided data.

Income Statement

Profitability has been inconsistent: net income was negative in 2019, 2020, 2022, and 2023, before turning modestly positive in 2024 ($2.4M). EBITDA is sizable and improved versus 2022–2023, but revenue and margin detail is largely unavailable (reported as 0), limiting visibility into core operating momentum and the quality of earnings.

Balance Sheet

The balance sheet appears conservatively structured with no debt reported and a stable equity base (~$69.5M in 2024) against total assets of ~$71.3M. Returns on equity have been volatile (negative in multiple years, positive in 2024 at ~3.5%), suggesting the capital base is not consistently generating strong profits despite the low leverage.

Cash Flow

Cash generation has been uneven: operating and free cash flow were negative in 2019–2020, turned positive in 2021–2023, then show as 0 in 2024 alongside a -100% free cash flow growth figure (suggesting weak/unclear latest-year cash conversion). Where available, operating cash flow exceeded net income in 2022–2023 (coverage above 3x), a positive sign, but the latest period reduces confidence in durability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	76.09M	264.78M	238.61M	115.99M	153.43M	197.84M
Net Income	4.43M	2.43M	-4.94M	-10.25M	1.24M	-1.95M
Balance Sheet
Total Assets	70.52M	71.31M	70.61M	81.71M	80.72M	71.31M
Cash, Cash Equivalents and Short-Term Investments	0.00	0.00	0.00	0.00	0.00	0.00
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.80M	1.80M	2.25M	7.68M	4.85M	4.99M
Stockholders Equity	68.72M	69.52M	68.36M	74.03M	75.87M	66.33M
Cash Flow
Free Cash Flow	0.00	0.00	6.98M	6.62M	1.15M	-2.44M
Operating Cash Flow	0.00	0.00	6.98M	6.62M	1.15M	-2.44M
Investing Cash Flow	6.97M	6.97M	6.98M	6.62M	5.56M	5.59M
Financing Cash Flow	-5.23M	-6.97M	-6.98M	-6.62M	-5.56M	-5.59M

KP Tissue Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KPT, the sentiment is Positive. The current price of 10.9 is above the 20-day moving average (MA) of 10.74, above the 50-day MA of 10.44, and above the 200-day MA of 9.59, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 61.45 is Neutral, neither overbought nor oversold. The STOCH value of 53.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:KPT.

KP Tissue Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CSW.A	74 Outperform	C$411.20M	11.92	15.23%	6.34%	8.87%	10.15%
RSI	73 Outperform	C$851.35M	6.68	14.63%	5.99%	6.57%	8.61%
CSW.B	72 Outperform	C$411.20M	11.45	15.23%	6.57%	8.87%	10.15%
ADW.A	67 Neutral	C$243.22M	7.36	8.25%	4.71%	-2.11%	―
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
KPT	62 Neutral	C$110.15M	―	5.55%	7.04%	―	-39.19%
HLF	61 Neutral	C$464.37M	8.64	8.60%	4.83%	6.15%	-36.76%

KP Tissue Corporate Events

Kruger Products Secures $165 Million in Senior Unsecured Notes Offering

KP Tissue Inc. announced that Kruger Products Inc. has successfully closed a CDN $165 million offering of senior unsecured notes due in 2032. The proceeds from this offering will be used to repay existing borrowings and for general corporate purposes. Additionally, KPI’s syndicated credit agreement has been amended to increase its facility amount and add Kruger Products SB Inc. as a restricted credit party, which could enhance the company’s financial flexibility and operational capacity.

The most recent analyst rating on (TSE:KPT) stock is a Hold with a C$11.00 price target. To see the full list of analyst forecasts on KP Tissue stock, see the TSE:KPT Stock Forecast page.

Kruger Products Inc. Announces $165 Million Senior Unsecured Notes Offering

KP Tissue Inc. announced that Kruger Products Inc. will issue and sell CDN $165 million in Senior Unsecured Notes due in 2032 through a private placement, with the offering expected to close on December 10, 2025. The proceeds from this offering will be used to repay borrowings under Kruger Products SB Inc.’s senior credit facilities and for general corporate purposes, potentially strengthening KPI’s financial position and operational flexibility.

The most recent analyst rating on (TSE:KPT) stock is a Hold with a C$11.00 price target. To see the full list of analyst forecasts on KP Tissue stock, see the TSE:KPT Stock Forecast page.

Kruger Products Announces $165 Million Notes Offering to Enhance Credit Profile

KP Tissue Inc. announced that Kruger Products Inc. plans to offer CAD $165 million in Senior Unsecured Notes through a private placement. The proceeds will be used to repay borrowings under Kruger Products SB Inc.’s senior credit facilities and for general corporate purposes, which is expected to improve the credit profile of the restricted group. The Notes will not be registered under U.S. or Canadian securities laws, and the offering is subject to market conditions.

The most recent analyst rating on (TSE:KPT) stock is a Hold with a C$11.00 price target. To see the full list of analyst forecasts on KP Tissue stock, see the TSE:KPT Stock Forecast page.

KP Tissue Reports Q3 Growth and Announces New Facility

KP Tissue Inc. reported a 7.7% increase in revenue for Q3 2025, reaching $561.1 million, driven by higher sales volumes and favorable pricing. The company also announced plans to build a new TAD tissue facility by 2028 to support its growth in ultra-premium products, reflecting its strategic focus on expanding market share and enhancing operational capacity.

The most recent analyst rating on (TSE:KPT) stock is a Hold with a C$10.00 price target. To see the full list of analyst forecasts on KP Tissue stock, see the TSE:KPT Stock Forecast page.

KP Tissue Reports Strong Q3 2025 Growth and Announces New Facility

KP Tissue Inc. reported a 7.7% increase in revenue to $561.1 million for Q3 2025, with Adjusted EBITDA rising by 30.4% to $85.7 million, driven by higher sales volumes and favorable pricing. Despite a decrease in net income due to foreign exchange losses and increased tax expenses, the company is focusing on long-term growth by announcing the construction of a new TAD tissue facility set to begin operations in 2028, aiming to meet the rising demand for ultra-premium products.

The most recent analyst rating on (TSE:KPT) stock is a Hold with a C$10.00 price target. To see the full list of analyst forecasts on KP Tissue stock, see the TSE:KPT Stock Forecast page.

KP Tissue Announces Quarterly Dividend and Reinvestment Plan

KP Tissue Inc. announced a quarterly dividend of $0.18 per common share, payable on January 15, 2026, to shareholders of record as of December 31, 2025. This dividend declaration is linked to a corresponding distribution by Kruger Products Inc., in which KPT holds a 12.1% interest. Additionally, KPT offers a Dividend Reinvestment Plan (DRIP) for Canadian shareholders, allowing them to reinvest cash dividends into additional common shares, subject to specific conditions and eligibility requirements.

The most recent analyst rating on (TSE:KPT) stock is a Hold with a C$10.00 price target. To see the full list of analyst forecasts on KP Tissue stock, see the TSE:KPT Stock Forecast page.